A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Inclusion Criteria: * 18\~59 years old at the time of screening. * Should not have received any meningococcal vaccine in the last 3 years. * Volunteers have given informed consent, have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete the 180-day study follow-up visit. * Volunteers have given informed consent, have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete the 180-day study follow-up visit. * Willingness to discuss medical history with the investigator or physician and to allow access to all medical records relevant to this trial. Exclusion Criteria: * Fever before vaccination, axillary temperature \>37.0°C. * History of epilepsy, convulsions or seizures or history or family history of psychiatric disorders. * Volunteers with current meningitis or a history of meningitis. * Blood pregnancy-positive or breastfeeding women with a planned pregnancy within 180 days of the volunteer or her partner. * Hypersensitivity to an ingredient or excipient of the medicinal product used in this clinical trial (mainly: group A meningococcal podophyllotoxin, group C meningococcal podophyllotoxin, group Y meningococcal podophyllotoxin, group W135 meningococcal podophyllotoxin, sucrose, mannitol, sodium chloride, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen p…